Amgen (NASDAQ: AMGN) announced that the company has decided to postpone indefinitely its planned design and build-out of a bulk manufacturing facility in Cork, Ireland.
Amgen has two manufacturing facilities in Boulder and Longmont, Colorado. Longmont is responsible for bulk manufacture of Epogen and Aranesp. Boulder manufactures Kineret, Kepivance and a number of product candidates in late-stage clinical development.
Capacity at the Boulder facility was recently increased; combine this with Cork coming off line and it may be safe to say that the Amgen-Colorado imprint shall continue to thrive.
For more CLSDF coverage on the Amgen and Colorado connection click (here).
If you enjoyed this post get free email updates (here).
No comments:
Post a Comment